June 6-11, 2010
The manufacture of medicines is increasingly globalised but biological products such as vaccines are more complex and their production raises significantly different issues to that of chemical entities. New producers in any region of the world may have difficulty in recognising all the concerns involved and can benefit from technology transfer exercises and a strong and scientifically competent regulatory authority. The issues will be discussed in the context of the Global Polio Eradication Initiative in its terminal phases and future needs for the manufacture of polio vaccine.
Philip Minor, "THE GLOBAL MANUFACTURE OF POLIO VACCINE IN THE ENDGAME OF ERADICATION" in "Vaccine Technology III", John G. Auniņš,Merck, USA; Barry C. Buckland, BiologicB, USA; Kathrin U. Jansen, Pfizer, USA; Paula Marques Alves, IBET, Portugal Eds, ECI Symposium Series, (2010). https://dc.engconfintl.org/vaccine_iii/17